AstraZeneca PLC

AZN Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.

Revenue
+6.70%
EPS
+22.5%
Free cash flow
+1.99%
Total debt
+1.75%

Quarter to September 2026, against a year earlier

187.20 1.81 −0.96%
Market cap
$289.8B
P/E
26.3×
Fwd P/E
24.5×
Dividend yield
1.71%
F-score
9/9
Altman Z
3.52
Beneish M
−2.51
Dividend safety
54/100

AstraZeneca PLC (AZN) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, AstraZeneca PLC (AZN) trades at a EV/FCF of 49.5×. Over the past ten years it has ranged from 18.3× (December 2017) to 98.2× (November 2018); the current reading is higher than 90% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 33.3× 10.48%
FY2024 30.2× (7.19%)
FY2023 32.5× 11.10%
FY2022 29.2× (31.97%)
FY2021 43.0× (3.01%)
FY2020 44.3× (18.54%)
FY2019 54.4× 78.91%
FY2018 30.4× 3.88%
FY2017 29.3× 20.77%
FY2016 24.2× (55.82%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 43.2× (15.01%)
Jun 2026 50.8× 22.39%
Mar 2026 41.5× 24.69%
Dec 2025 33.3× 26.85%
43 more quarters

Against its own ten years

Low 18.3× High 98.2×
Ten-year median 35.2×
Current reading's percentile 89

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on AZN